<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052493</url>
  </required_header>
  <id_info>
    <org_study_id>ICIM1420/09/01</org_study_id>
    <secondary_id>2009-017522-39</secondary_id>
    <nct_id>NCT01052493</nct_id>
  </id_info>
  <brief_title>A First-Time-in-Human Study to Assess the Safety and Tolerability of PP 1420 in Healthy Subjects</brief_title>
  <official_title>A First Time in Human, Double Blind, Randomised, Placebo Controlled Dose Escalation Study to Assess the Safety and Tolerability of PP 1420 in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      When humans eat, the bowels naturally secrete chemicals into the bloodstream which make&#xD;
      people feel full and which stop eating. One of these chemicals is known as &quot;Pancreatic&#xD;
      Polypeptide&quot; (PP). We have previously shown that injections of human PP reduces appetite and&#xD;
      food intake. We have now developed a very similar chemical, PP 1420, as a treatment for&#xD;
      obesity. PP 1420 has been tested in animals and has been shown to be safe, and to reduce&#xD;
      their appetite. This study will test PP 1420 for its safety and tolerability in humans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      More than 20 percent of people in the UK are obese. People with obesity have a shorter life&#xD;
      expectancy, and have a higher risk of having heart attacks, strokes, high blood pressure,&#xD;
      diabetes, and certain cancers.&#xD;
&#xD;
      At the moment, there is no treatment for obesity that is both effective and safe. Advising&#xD;
      people to change their diet and to exercise more is frequently ineffective, and any loss in&#xD;
      weight seen is usually temporary. There are a couple of licensed medications for the purpose&#xD;
      of losing weight, but they are limited by side effects. Finally, gastric bypass and similar&#xD;
      surgeries are effective at reducing weight permanently, but it can be risky and is restricted&#xD;
      only to very motivated people.&#xD;
&#xD;
      &quot;Gut hormones&quot; are natural chemicals made by the bowels when you eat. They work to reduce&#xD;
      appetite and hunger when you eat, so that you will eat enough for your needs. We think that&#xD;
      one of the reasons why gastric bypass surgery is so effective is because the surgery causes&#xD;
      an increase in gut hormone secretion into the bloodstream, which suppresses appetite. One of&#xD;
      these hormones is pancreatic polypeptide (PP), which is released into the bloodstream by&#xD;
      cells in the pancreas after eating. When human PP is given to healthy volunteers as an&#xD;
      injection, we see that they have a reduced appetite and food intake with no side effects such&#xD;
      as feeling sick or vomiting.&#xD;
&#xD;
      Human PP does not last long in the blood stream. In order to make it into a new, safe and&#xD;
      effective drug for obesity, we have developed a new form of PP, which is very similar but not&#xD;
      identical to human PP, that we expect will last longer in the blood. We call this PP 1420.&#xD;
&#xD;
      In testing, PP 1420 reduced food intake in animals, and was safe in them at much higher doses&#xD;
      than those we plan to give in the current study. This study will assess the safety and&#xD;
      tolerability of PP 1420 in humans, and is the first time humans have been given this&#xD;
      medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2010</start_date>
  <completion_date type="Actual">October 18, 2010</completion_date>
  <primary_completion_date type="Actual">October 18, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>There were three dosing periods. Each subject (n=12) was randomised to receive up to two doses of placebo and/or up to three ascending doses of PP 1420 dosed as s.c. injection. During each dosing period eight subjects received active drug and four received placebo. Subjects could also be randomised to receive one further dose of PP 1420 or placebo, if needed, to explore an intermediate dose based upon a review of safety, tolerability, and PK data from the previous cohorts.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This was a double-blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Adverse Events (AEs)</measure>
    <time_frame>7-12 weeks</time_frame>
    <description>Number of subjects with adverse events recorded through the trial period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-t(Last)</measure>
    <time_frame>24 hours</time_frame>
    <description>The area under the concentration vs. time curve of PP 1420 from time zero to the last sampling time, calculated by the linear trapezoidal rule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>24 hours</time_frame>
    <description>the area under the concentration vs. time curve for PP 1420, estimated from time zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Drug Concentration (Cmax)</measure>
    <time_frame>Within 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Observed Concentration (Tmax)</measure>
    <time_frame>Within 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (t½)</measure>
    <time_frame>Within 24 hours</time_frame>
    <description>Calculated from log 2/λz where λz is the apparent terminal rate constant.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>2mg PP 1420</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PP 1420 single dose, subcutaneous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4mg PP 420</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PP 1420 single dose, subcutaneous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8mg PP 1420</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PP 1420 single dose, subcutaneous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PP 1420</intervention_name>
    <description>Single dose of PP 1420, administered subcutaneously at either 2mg, 4mg or 8mg.</description>
    <arm_group_label>2mg PP 1420</arm_group_label>
    <arm_group_label>4mg PP 420</arm_group_label>
    <arm_group_label>8mg PP 1420</arm_group_label>
    <other_name>PP 1420 pancreatic polypeptide analog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male as determined by a responsible physician, based on a medical evaluation&#xD;
             including history, physical examination, vital signs, laboratory tests and 12-lead&#xD;
             ECG.&#xD;
&#xD;
          -  Between 18 and 50 years of age, inclusive, at the time of signing and dating the&#xD;
             informed consent form.&#xD;
&#xD;
          -  Body weight ≥70 kg and body mass index (BMI) within the range 18 - 35 kg/m2&#xD;
             (inclusive).&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  Willing and able to comply with the protocol for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  As a result of the medical interview, physical examination, or screening&#xD;
             investigations, the Investigator considers the subject unsuitable for the study.&#xD;
&#xD;
          -  The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that&#xD;
             will be screened for include amphetamines, barbiturates, cocaine, opiates,&#xD;
             cannabinoids and benzodiazepines.&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             result within 3 months of screening.&#xD;
&#xD;
          -  A positive test for human immunodeficiency virus (HIV) antibody.&#xD;
&#xD;
          -  History of migraine.&#xD;
&#xD;
          -  History or evidence of abnormal eating behaviour, as observed through the Dutch Eating&#xD;
             Behaviour (DEBQ) and SCOFF questionnaires.&#xD;
&#xD;
          -  History of excessive alcohol consumption within 6 months of the study defined as an&#xD;
             average weekly intake of greater than 21 units or an average daily intake of greater&#xD;
             than 3 units. One unit is equivalent to 8 g of alcohol, a half-pint (approximately 240&#xD;
             mL) of beer or 1 measure (25 mL) of spirits or 1 glass (125 mL) of wine.&#xD;
&#xD;
          -  Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or&#xD;
             nicotine-containing products within 6 months prior to screening.&#xD;
&#xD;
          -  Has QTc at screening &gt;450 msec.&#xD;
&#xD;
          -  Systolic blood pressure outside the range 85 - 160 mmHg, diastolic blood pressure&#xD;
             outside the range 45 - 100 mmHg, and/or heart rate outside the range 40 - 110 bpm.&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the dosing day in the current study:&#xD;
             90 days, five half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements within 14 days or five half-lives (whichever is longer) prior to the dose&#xD;
             of study medication, which, in the opinion of the Investigator, may interfere with the&#xD;
             study procedures or compromise subject safety.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the Investigator,&#xD;
             contraindicates their participation.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood in excess of 500 mL&#xD;
             within 3 months before or after the study.&#xD;
&#xD;
          -  Unwilling to abstain from consumption of caffeine- or xanthine- containing products&#xD;
             for 24 hours prior to dosing until the post-dose assessment at each treatment level.&#xD;
&#xD;
          -  Unwilling to abstain from use of illicit drugs.&#xD;
&#xD;
          -  Unwilling to abstain from alcohol for 48 hours prior to dosing until final post-dose&#xD;
             assessment at each treatment level.&#xD;
&#xD;
          -  Unwilling to abstain from smoking or otherwise consuming tobacco for 24 hours prior to&#xD;
             dosing until the post-dose assessment at each treatment level.&#xD;
&#xD;
          -  Unwilling to use a condom during sexual activity from first dose until the end of the&#xD;
             study.&#xD;
&#xD;
          -  Vegans and subjects with milk or wheat intolerance or allergy as reported by the&#xD;
             subject.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Healthy male</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Bloom FRCP DSc, MB BChir</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sir John McMichael Centre for Clinical Studies, Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, Frost GS, Ghatei MA, Bloom SR. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab. 2003 Aug;88(8):3989-92.</citation>
    <PMID>12915697</PMID>
  </reference>
  <reference>
    <citation>Jesudason DR, Monteiro MP, McGowan BM, Neary NM, Park AJ, Philippou E, Small CJ, Frost GS, Ghatei MA, Bloom SR. Low-dose pancreatic polypeptide inhibits food intake in man. Br J Nutr. 2007 Mar;97(3):426-9.</citation>
    <PMID>17313701</PMID>
  </reference>
  <results_reference>
    <citation>Tan TM, Field BC, Minnion JS, Cuenco-Shillito J, Chambers ES, Zac-Varghese S, Brindley CJ, Mt-Isa S, Fiorentino F, Ashby D, Ward I, Ghatei MA, Bloom SR. Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. Br J Clin Pharmacol. 2012 Feb;73(2):232-9. doi: 10.1111/j.1365-2125.2011.04082.x.</citation>
    <PMID>21834938</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 19, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <results_first_submitted>July 11, 2012</results_first_submitted>
  <results_first_submitted_qc>January 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 12, 2021</results_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>pancreatic polypeptide</keyword>
  <keyword>gut hormones</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Polypeptide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment at Sir John McMichael Centre, Hammersmith Hospital</recruitment_details>
      <pre_assignment_details>12 participants started the study. It was a sequential cross-over study. They were randomised to receive either PP 1420 or placebo at each treatment stage. After the first treatment period, one volunteer withdrew. This participant was replaced with a new participant in order that 12 participants progressed onto intervention periods 2 and then 3.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo, 4mg PP 1420, 8mg PP 1420</title>
          <description>Intervention Period 1: Placebo Intervention period 2: 4mg PP 1420 Intervention period 3: 8mg PP 1420</description>
        </group>
        <group group_id="P2">
          <title>2mg PP 1420, Placebo, 8mg PP 1420</title>
          <description>Intervention Period 1: 2mg PP 1420 Intervention Period 2. Placebo Intervention Period 3. 8mg PP 1420</description>
        </group>
        <group group_id="P3">
          <title>2mg PP 1420, 4mg PP 1420, Placebo</title>
          <description>Intervention Period 1: 2mg PP 1420 Intervention Period 2. 4mg PP 1420 Intervention Period 3. Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intervention 1 (Up to 10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period 1 (up to 5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention 2 (up to 10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4">Replacement subject recruited</participants>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 2 (up to 5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention 3 (up to 10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The population of participants which started in dosing period 1</population>
      <group_list>
        <group group_id="B1">
          <title>All Participant</title>
          <description>Crossover, sequential study with all participant</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.0" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Adverse Events (AEs)</title>
        <description>Number of subjects with adverse events recorded through the trial period</description>
        <time_frame>7-12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2mg PP 1420</title>
            <description>Single dose of PP 1420, administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>4mg PP 1420</title>
            <description>Single dose of PP 1420, administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>8mg PP 1420</title>
            <description>Single dose of PP 1420, administered subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>0.9% saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events (AEs)</title>
          <description>Number of subjects with adverse events recorded through the trial period</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total number of AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t(Last)</title>
        <description>The area under the concentration vs. time curve of PP 1420 from time zero to the last sampling time, calculated by the linear trapezoidal rule</description>
        <time_frame>24 hours</time_frame>
        <population>PP 1420 arms only</population>
        <group_list>
          <group group_id="O1">
            <title>2mg PP 1420</title>
            <description>Single dose of PP 1420, administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>4mg PP 1420</title>
            <description>Single dose of PP 1420, administered subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>8mg PP 1420</title>
            <description>Single dose of PP 1420, administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t(Last)</title>
          <description>The area under the concentration vs. time curve of PP 1420 from time zero to the last sampling time, calculated by the linear trapezoidal rule</description>
          <population>PP 1420 arms only</population>
          <units>ng ml-1 h</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.6" lower_limit="49.7" upper_limit="126"/>
                    <measurement group_id="O2" value="229" lower_limit="107" upper_limit="316"/>
                    <measurement group_id="O3" value="403" lower_limit="205" upper_limit="589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-∞</title>
        <description>the area under the concentration vs. time curve for PP 1420, estimated from time zero to infinity</description>
        <time_frame>24 hours</time_frame>
        <population>PP 1420 arms only</population>
        <group_list>
          <group group_id="O1">
            <title>2mg PP 1420</title>
            <description>Single dose of PP 1420, administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>4mg PP 1420</title>
            <description>Single dose of PP 1420, administered subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>8mg PP 1420</title>
            <description>Single dose of PP 1420, administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞</title>
          <description>the area under the concentration vs. time curve for PP 1420, estimated from time zero to infinity</description>
          <population>PP 1420 arms only</population>
          <units>ng ml-1 h</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" lower_limit="67.6" upper_limit="131"/>
                    <measurement group_id="O2" value="241" lower_limit="109" upper_limit="356"/>
                    <measurement group_id="O3" value="418" lower_limit="210" upper_limit="600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Drug Concentration (Cmax)</title>
        <time_frame>Within 24 hours</time_frame>
        <population>PP 1420 arms only</population>
        <group_list>
          <group group_id="O1">
            <title>2mg PP 1420</title>
            <description>Single dose of PP 1420, administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>4mg PP 1420</title>
            <description>Single dose of PP 1420, administered subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>8mg PP 1420</title>
            <description>Single dose of PP 1420, administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Drug Concentration (Cmax)</title>
          <population>PP 1420 arms only</population>
          <units>ng ml-1</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" lower_limit="15.9" upper_limit="39.1"/>
                    <measurement group_id="O2" value="55.1" lower_limit="37.5" upper_limit="74.2"/>
                    <measurement group_id="O3" value="95.7" lower_limit="74.2" upper_limit="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Observed Concentration (Tmax)</title>
        <time_frame>Within 24 hours</time_frame>
        <population>PP 1420 arms only</population>
        <group_list>
          <group group_id="O1">
            <title>2mg PP 1420</title>
            <description>Single dose of PP 1420, administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>4mg PP 1420</title>
            <description>Single dose of PP 1420, administered subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>8mg PP 1420</title>
            <description>Single dose of PP 1420, administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Observed Concentration (Tmax)</title>
          <population>PP 1420 arms only</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.875" lower_limit="0.32" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.75" upper_limit="1.50"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.50" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-life (t½)</title>
        <description>Calculated from log 2/λz where λz is the apparent terminal rate constant.</description>
        <time_frame>Within 24 hours</time_frame>
        <population>PP 1420 arms only</population>
        <group_list>
          <group group_id="O1">
            <title>2mg PP 1420</title>
            <description>Single dose of PP 1420, administered subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>4mg PP 1420</title>
            <description>Single dose of PP 1420, administered subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>8mg PP 1420</title>
            <description>Single dose of PP 1420, administered subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (t½)</title>
          <description>Calculated from log 2/λz where λz is the apparent terminal rate constant.</description>
          <population>PP 1420 arms only</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42" lower_limit="1.64" upper_limit="3.38"/>
                    <measurement group_id="O2" value="2.49" lower_limit="1.69" upper_limit="3.60"/>
                    <measurement group_id="O3" value="2.61" lower_limit="2.13" upper_limit="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7-12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>2mg PP 1420</title>
          <description>Single dose of PP 1420, administered subcutaneously.</description>
        </group>
        <group group_id="E2">
          <title>4mg PP 1420</title>
          <description>Single dose of PP 1420, administered subcutaneously.</description>
        </group>
        <group group_id="E3">
          <title>8mg PP 1420</title>
          <description>Single dose of PP 1420, administered subcutaneously.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>0.9% saline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain/bloating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infected finger</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cold sore</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction/bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Tricia Tan</name_or_title>
      <organization>Imperial College London</organization>
      <phone>020 83838038</phone>
      <email>t.tan@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

